The tablet and the injection are priced differently on this roster, and the gap has its own page. This is what the clinical evidence behind that gap actually consists of.
What the review gathered
Thirty studies — 12 randomized trials, nine systematic reviews, five comparative or observational studies and four pharmacokinetic studies — searched to June 2025 in adults with a BMI of 27 or above. [1] Both formulations significantly improved glycated hemoglobin, blood pressure and lipids. Oral semaglutide showed better patient preference and equivalent adherence among people averse to needles.
The number with a cost attached
Oral semaglutide reaches roughly 1% bioavailability. The injection reaches roughly 89%. To deliver a comparable effect, the tablet is dosed at 50 mg daily where the injection is 2.4 mg weekly — about twenty times the active ingredient per dose, and far more than that across a week.
That is arithmetic on published doses rather than a claim about anybody’s costs, and it explains something otherwise puzzling. A tablet is cheaper to ship, needs no cold chain and requires no needle, so the intuition is that it should cost less. It contains vastly more drug.
On this roster the tablet runs a median of $20 more a month than the injection, measured only on the 73 sellers publishing a figure for both, read September 2026, with 39 of them charging more for it. Whether that gap tracks ingredient cost, convenience pricing, or something else is not answerable from a price list — the current spread is all a buyer can see.
The ingredient that has to be there
One per cent absorption is not achieved by the drug alone. The approved oral formulation co-administers semaglutide with SNAC, an absorption enhancer that protects the peptide in the stomach and helps it cross the lining. Without it, an oral peptide is largely digested.
That matters here because this roster sells oral semaglutide, and most of it is compounded. Whether any particular compounded tablet replicates the approved formulation’s absorption chemistry is not something this desk knows, and it is not something a buyer can verify from a product page. It is a question worth asking a seller, in the same way that what evidence exists for a specific product is worth asking.
What the review concludes, and what it does not
It concludes that oral semaglutide 50 mg is a clinically valid alternative for people who prefer to avoid needles, with equivalent efficacy and a better patient experience. That is a reasonable reading of thirty studies.
It does not conclude that the two formats have been compared, because they have not. The same absence turned up when kidney outcomes were pooled across an oral and two injected arms — nobody ran that comparison either. For a buyer choosing between formats on this roster, the honest position is that the formats look similar across separate trials, the price difference is real, and no study has put them side by side.